

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

APPENDIX 5
FORMS RELATING TO LISTING
FORM F
GEM
COMPANY INFORMATION SHEET

Case Number: N/A

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: China Regenerative Medicine International Limited

Stock code (ordinary shares): 8158

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on GEM of The Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 30 December, 2021.....

A. General

Place of incorporation: Cayman Islands

Date of initial listing on GEM: 18 July, 2001

Name of Sponsor(s): N/A

Names of directors:
(please distinguish the status of the directors - Executive, Non-Executive or Independent Non-Executive)

Executive Director
Mr. Wang Chuang (Chairman and Chief Executive Officer)

Non-Executive Director
Mr. Tsang Ho Yin

Independent non-executive Directors

Ms. Huo Chunyu
Dr. Liu Ming
Mr. Leung Man Fai

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	<p>1. All Favour Holdings Limited is interested in 582,547,765 shares of the Company, representing: approximately 20.41% of the issued share capital of the Company (Note 1).</p> <p>Note 1: All Favour Holdings Limited is beneficially owned as to (i) 40% by Nat-Ace Wood Industry Ltd.; (ii) 20% by Honour Top Holdings Limited; and (iii) 40% by Mr. Dai Yumin ("Mr. Dai"), respectively. Honour Top Holdings Limited is wholly owned by Mr. Dai and Nat-Ace Wood Industry Ltd. is wholly owned by Mr. Li Ren ("Mr. Li"). Mr. Li is deemed to be interested in 582,547,765 shares of the Company in which All Favour Holding Limited is interested in.</p> <p>2. Mr. Li personally owns 21,380,000 shares of the Company. Mr. Li is therefore deemed to be interested in an aggregate of 603,927,765 shares of the Company, representing, approximately 21.16% of the issued share capital of the Company.</p> <p>3. Mr. Wang Chuang is interested in 538,670,000 shares of the Company, representing: approximately 18.87% of the issued share capital of the Company</p>
Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:	Not Applicable
Financial year end date:	31 December
Registered address:	<p>Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands</p>
Head office and principal place of business:	Suite 2310-2318, Miramar Tower, 132 Nathan Road, Tsim Sha Tsui, Hong Kong
Web-site address (if applicable):	www.crimi.hk
Share registrar:	<p>Principal Share Registrar Conyers Trust Company (Cayman) Limited Cricket Square, Hutchins Drive P.O. Box 2681 Grand Cayman, KY1-1111 Cayman Islands</p> <p>Hong Kong Branch Share Registrar Union Registrars Limited Suites 3301-04, 33/F, Two Chinachem Exchange Square, 338 King's Road North Point Hong Kong</p>
Auditors:	McM (HK) CPA Limited

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

B. Business activities

(Please insert here a brief description of the business activities undertaken by the Company and its subsidiaries.)

The Company is an investment holding company and the principal activities of its subsidiary are provision of medical beauty services and healthcare products.

C. Ordinary shares

Number of ordinary shares in issue: 2,854,289,500

Par value of ordinary shares in issue: HKD 0.20 per share

Board lot size (in number of shares): 5,000 shares per lot size

Name of other stock exchange(s) on which ordinary shares are also listed: N/A

D. Warrants

Stock code: N/A

Board lot size: N/A

Expiry date: N/A

Exercise price: N/A

Conversion ratio: N/A
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding: N/A

No. of shares falling to be issued upon the exercise of outstanding warrants: N/A

E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

(A) Reference is made to the announcement of the Company dated 16 September 2015 regarding the option grant (the "2015 Grant"). Further information of the Options are as follows: -

Date of Grant: 16 September 2015

Option Period: 16 September 2015 - 15 September 2025 (both days inclusive)

Adjusted Exercise Price: HK\$9.00 per share

No. of new shares which may be issued upon the exercise of Options under the 2015 Grant as at the date hereof: 3,302,000 ordinary shares of the Company

(B) Reference is made to the announcement of the Company dated 9 September 2016 regarding the option grant (the "2016 Grant"). Further information of the Options are as follows: -

Date of Grant: 9 September 2016

Option Period: 9 September 2016 - 8 September 2025 (both days inclusive)

Adjusted Exercise Price: HK\$5.82 per share

No. of new shares which may be issued upon the exercise of Options under the 2016 Grant as at the date hereof: 4,936,500 ordinary shares of the Company

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Submitted by: Lei Ming Fung
(Name)

Title: Company Secretary
(Director, secretary or other duly authorised officer)

NOTE

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.